To the Editors,

We read with interest the article by Martin Arranz et al^[@CIT0001]^ conducting a national survey among inflammatory bowel disease (IBD) gastroenterologists to investigate the changes in practice, IBD treatments, and diagnosis and treatment of COVID-19 in IBD units during the COVID-19 pandemic. They found many changes in structure, diagnosis of COVID-19, and modifications in IBD treatments within IBD units. We agree with these findings and organized a questionnaire that included alterations in the mode of medical treatment and medical consultation in patients with IBD during the COVID-19 pandemic.

Two hundred thirty-nine patients with IBD (29.71% were patients with Crohn disease, 63.18% were patients with ulcerative colitis, and 7.11% had suspected cases of IBD that had not been confirmed) participated in the questionnaire, including 108 women (45.19%) and 131 men (54.81%). Some of the changes that occurred with the medical treatment and medical mode of patients with IBD are shown in [Table 1](#T1){ref-type="table"}). The results showed that 20.6% of patients preferred to buy drugs online before the COVID-19 pandemic, whereas the number of such patients had increased to 28.97% during the COVID-19 pandemic. Before the COVID-19 pandemic, 53.4% of patients used 5-aminosalicylates, 3.7% used corticosteroids, 12.65% used immunosuppressive drugs, and 14.2% used biologic therapies. However, during the pandemic, 52 patients (21.76%) had changed their medications and 31.14% complained that they could not buy enough drugs or inject infliximab on time. The main reason was that many hospitals have been unable to open and treat patients who were not diagnosed with COVID-19 (66.67%). Thus 41 patients (17.15%) had delayed the use of infliximab injection therapy, and 36 of these patients (87.8%) had delayed for more than 2 weeks. Most of these patients (70.49%) had to stop biologic therapies.

###### 

Demographic and Clinical Features of 239 Patients With IBD

                                                Did Not Change Medication   Changed Medication
  --------------------------------------------- --------------------------- --------------------
  Participants (%)                              187 (78.24)                 52 (21.76)
  Gender (%)                                                                
   Male                                         100 (53.48)                 31 (59.62)
   Female                                       87 (46.52)                  21 (40.38)
  Disease (%)                                                               
   CD                                           57 (30.48)                  14 (26.92)
   UC                                           119 (63.64)                 32 (61.54)
   Undiagnosed                                  11 (5.88)                   6 (11.54)
  Age, y (%)                                                                
   ≤16                                          3 (1.60)                    0 (0)
   16\~40 (\>16, ≤40)                           82 (43.85)                  32 (61.54)
   40\~65 (\>40, ≤65)                           90 (48.13)                  20 (38.46)
   \>65                                         12 (6.42)                   0 (0)
  Time of last treatment (%)                                                
   ≤3 mo                                        50 (26.74)                  20 (38.46)
   3\~6 mo (\>3 mo, ≤6 mo)                      43 (22.99)                  13 (25)
   6\~12 mo (\>6 mo, ≤12 mo)                    44 (23.53)                  11 (21.15)
   \>12 mo                                      50 (26.74)                  8 (15.38)
  Course of disease                                                         
   ≤2 y                                         99 (52.94)                  30 (57.69)
   2\~5 y (\>2 y, ≤5 y)                         46 (24.60)                  10 (19.23)
   5\~10 y (\>5 y, ≤10 y)                       26 (13.90)                  8 (15.38)
   \>10 y                                       16 (8.56)                   4 (7.69)
  Medication use before COVID-19 pandemic (%)                               
   5-ASA                                        132 (61.11)                 34 (53.13)
   Corticosteroid                               7 (3.24)                    5 (7.81)
   Immunosuppressive                            30 (13.89)                  9 (14.06)
   Biologic therapy                             35 (16.20)                  11 (17.19)
   Other                                        12 (5.56)                   5 (7.81)
  Medication use during COVID-19 pandemic (%)                               
   5-ASA                                        126 (62.07)                 33 (56.90)
   Corticosteroid                               3 (1.48)                    3 (5.17)
   Immunosuppressive                            27 (13.30)                  7 (12.07)
   Biologic therapy                             31 (15.27)                  11 (18.97)
   Other                                        16 (7.88)                   4 (6.90)
  Reason for changing medications                                           
   Not enough drugs                             ---                         10 (16.39)
   No biologic therapy                          ---                         9 (14.75)
   Self-reducing drug                           ---                         10 (16.39)
   Reduce medicine according to physician       ---                         15 (24.59)
   Other                                        ---                         17 (27.87)
  Disease stability (%)                                                     
   Stable                                       152 (81.28)                 36 (69.23)
   Unstable                                     35 (18.72)                  16 (30.77)
  Whether to delay use of biologics (%)                                     
   Unused                                       139 (74.33)                 34 (65.38)
   No                                           19 (10.16)                  6 (11.54)
   Yes                                          29 (15.51)                  12 (23.08)

CD indicates Crohn disease; 5-ASA, 5-aminosalicylate; UC, ulcerative colitis.

During the COVID-19 pandemic, 188 patients with IBD (78.66%) were in stable condition, and 51 patients (21.34%) had fever, abdominal pain, diarrhea, hematochezia, vomiting, and joint pain were related to IBD. And these patients received regular IBD treatments at our IBD center were inpatients and outpatients. In addition, 43.79% patients chose an internet platform for medical consultation. Mobile communication such as WeChat accounted for 57.45% of online medical advice. The results of our study showed that there were significant differences in the mode of medical treatment, medical consultation and the method of buying drugs before and after the COVID-19 pandemic.

In conclusion, we found that the COVID-19 pandemic has affected patients with IBD in the mode of medical treatment, medical consultation, and method of buying medications. In addition, the number of patients with IBD using the internet for medical consultation is increasing.
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